Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rulseh, Aaron Michael, Keller, Jiří, Klener, Jan, Šroubek, Jan, Dbalý, Vladimír, Syrůček, Martin, Tovaryš, František, Vymazal, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514151/
https://www.ncbi.nlm.nih.gov/pubmed/23095807
http://dx.doi.org/10.1186/1477-7819-10-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514151/
https://www.ncbi.nlm.nih.gov/pubmed/23095807
http://dx.doi.org/10.1186/1477-7819-10-220

Ejemplares similares